COVID-19: Vanderbilt enrolls first patient in hydroxychloroquine study

COVID-19: Vanderbilt enrolls first patient in hydroxychloroquine study

Washington D.C, April 10: The National Institute of Health (NIH) on Thursday announced it has begun enrolling participants in a clinical trial to test the effectiveness of hydroxychloroquine, an anti-malarial drug, for treating COVID-19.

"These include hydroxychloroquine, kaletra, steroids and Remdesivir". He was given a five-day trial of the drug hydroxychloroquine.

In a statement to CNN, Dr. Kevin Tracey, president and chief executive officer of the Institutes Feinstein Medical Research, in the city of NY, also said that the trial was flawed and that it was "a complete failure".

All study participants will receive clinical care based on their condition, but those randomized to experimental intervention will also receive hydroxychloroquine, the drug President Trump has touted during his White House press briefings.

However, the drug does come with risks including cardiac arrhythmias, seizures, dermatological reactions and hypoglycemia.

The U.S. Food and Drug Administration on March 28 authorized the emergency use of hydroxychloroquine and chloroquine in hospitalized Covid-19 patients who can't participate in a clinical trial, allowing the U.S. government to distribute millions of doses donated by drug companies.

Study the power of the medication against the coronavirus.

Meanwhile, the publisher of the International Journal of Antimicrobial Agents has denounced a recent publication in the journal that hydroxychloroquine is effective against coronavirus following a study carried out on 20 patients in France.

The Outcomes Related to COVID-19 treated with hydroxychloroquine among In-patients with symptomatic Disease (ORCHID) study has started enrolling patients at the Vanderbilt University Medical Center in Nashville, Tennessee.

A spokesman for Barts said: "Barts Health NHS Trust has convened an expert clinical group to consider novel medications in the treatment of Covid-19".

The COVID-19 in general presents as an acute infectious disease of respiratory, but it can damage many areas of the body, including the heart, lungs, and the blood, according to the NIH. Two weeks later, he was declared recovered from the virus.

As of Saturday, more than 16 lakh people globally tested positive and more than one lakh have died.

In the wake of coronavirus outbreak, India, in March, had banned the export of hydroxychloroquine which could be used as potential anti-viral agent, and other generic medicines.

Four days after withdrawing a ban on the export of all anti-malaria drugs, the ministry of commerce has again imposed the ban on the medicines to stockpile them in case of their possible use to treat Covid-19 patients.

Related Articles